What Is Retatrutide? Structure, Receptors and Lab Characterization

The short definition

Retatrutide is a single-chain synthetic peptide engineered as a unimolecular agonist of three class B G-protein-coupled receptors: the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Its discovery and in vitro pharmacology were described in 2022 under the code LY3437943 ^[1]. "Tri-agonist" and "triple agonist" mean the same thing.

The name is a research name, not a brand. It sits in the same family as Tirzepatide, a dual GIP/GLP-1 agonist, and the extra glucagon-receptor activity is the feature that sets it apart; see Tirzepatide vs Retatrutide.

The three receptors

• GLP-1R: the receptor for glucagon-like peptide-1, a gut-derived incretin hormone.
• GIPR: the receptor for GIP, the other incretin hormone. Retatrutide was reported to be more potent at GIPR than at the other two in cell-based assays ^[1].
• GCGR: the receptor for glucagon. Reviews of glucagon agonism describe how this receptor is studied in energy-expenditure and liver-metabolism models ^[2].

All three belong to the same receptor class and the three native hormones are structurally related, which is why one peptide sequence can be tuned to engage all of them.

How the molecule is built

Retatrutide is a 39-residue peptide with a listed molecular weight of about 4731.3 Da and formula C221H342N46O68. Its backbone contains non-coded residues such as alpha-aminoisobutyric acid (Aib), and a fatty diacid is attached through a linker on a lysine side chain. The fatty acid binds serum albumin, which is the design feature associated with its long half-life in published pharmacokinetic work ^[1]. A recent review describes its molecular design and pharmaceutical development in more detail ^[3].

The formula contains no sulfur, so the peptide has no cysteine or methionine. That removes disulfide and methionine-oxidation questions that complicate many other peptides, as covered in the mass spectrometry guide.

Where it fits in the literature

Retatrutide has been evaluated by its developer in regulated clinical programs, starting with phase 2 reports ^[4]. Those programs are separate from research-grade material and are not discussed here as guidance of any kind. For laboratory work, the published preclinical and receptor-pharmacology papers are the relevant background; the Retatrutide research overview lists them with their limits.

How a research sample is characterized

Identity is confirmed by Mass spectrometry. At around 4.7 kDa the peptide shows a series of multiply charged ions in electrospray, so the neutral mass is reconstructed from several charge states and compared with the expected value. Purity is reported by HPLC area percent; because the molecule is lipidated and amphiphilic, retention is later and peaks can be broader than for unmodified peptides.

Label mass is not peptide mass: counter-ions and residual water make up part of a lyophilized powder, which the net peptide content guide explains. Lipidated peptides can also self-associate and stick to plastic, covered in the solubility and aggregation guide.

Handling and arithmetic

Retatrutide is supplied as a Lyophilized powder and stored sealed and frozen. The reconstitution calculator does concentration arithmetic from a vial mass and a solvent volume, and the vial size post explains how vial mass changes the numbers. Retatrutide is sold for laboratory research use only.